Life Science Compliance Update

February

2018

Has the Shine Worn Off False Claims QUI TAM Actions

Written by , Posted in Uncategorized

Gwendolyn Ball, Staff Writer, Life Science Compliance Update

At the recent HCCA Annual Conference, the Deputy Director of DOJ’s Civil Fraud Section may have signaled a change in policy relative to handling qui tam cases. This article explores the issue and what it might mean for life science companies going forward.


   or   

Topic tags:

February

2018

Revisiting the Past – Warner Chilcott vs. Insys

Written by , Posted in Uncategorized

Kaitlin Fallon Wildoner, Esq., Senior Staff Writer, Life Science Compliance Update

Those who remember the Warner Chilcott and W. Carl Reichel case from just two years ago may have had déjà vu when they heard about the recent legal controversy surrounding John N. Kapoor and Insys. This article reviews the current Insys and Kapoor developments and compares the two cases to analyze whether the trend of involving high-ranking executives is the future of enforcement.


   or   

Topic tags:

February

2018

One Purpose to Rule Them All – A Resounding “Yes” According to the District Court in U.S. EX Rel. Cairns

Written by , Posted in Uncategorized

Robert N. Wilkey, Esq., Staff Writer and Seth B. Whitelaw, J.D., LL.M., S.J.D., Editor for Life Science Compliance Update

The breadth of liability under the False Claims Act and Anti-Kickback Statute is a closely watched area. Recently, the U.S District Court for the Eastern District of Missouri concluded that liability might extend to a health care provider even where the plaintiff fails to demonstrate that the “primary purpose” of providing the benefits was to create an inducement. Although the impact of such Court case remains somewhat uncertain, it is expected that the Court’s ruling will continue to expand FCA and AKS liability


   or   


February

2018

Staring Down Another First Amendment Challenge – The OIG vs. Patient Services

Written by , Posted in Uncategorized

Kaitlin Fallon Wildoner, Esq., Senior Staff Writer, Life Science Compliance Update

Patient Assistance Programs (“PAPs”) are starting to feel the heat from various United States agencies, as we have noted in several issues over the past year. Recently, Patient Services, Inc., filed suit in response to a Modified Advisory Opinion issued by the HHS OIG. This article outlines the changes and the suit.


   or   


February

2018

When Good Intentions Go Astray – United Therapeutics Settles AKS Suit

Written by , Posted in Uncategorized

Kaitlin Fallon Wildoner, Esq., Senior Staff Writer, Life Science Compliance Update

With the United Therapeutics settlement, it is clear that the DOJ remains focused on patient assistance programs and other similar charities. As a result, additional settlements involving these programs are likely to continue in 2018, once more pitting established legal constructs against current fiscal realities.


   or   


October

2017

Getting Serious About Fraud – The DOJ Charges 412

Written by , Posted in Uncategorized

Kaitlin Fallon Wildoner, Esq., Senior Staff Writer, Life Science Compliance Update

With the new administration, there appears to be a renewed commitment to enforcing anti-kickback rules against healthcare providers committing fraud against the government insurance programs. In July 2017, the Department of Justice and Department of Health and Human Services announced the largest-ever fraud takedown in the health care arena. This article outlines the announcement, and what it may mean for the future of health care.


or

Topic tags:

Gravityscan Badge
Menu Title